Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2018 20:01 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Declaratory Judgment Action Filed by Osmotica Related to Approved OSMOLEX ER

EMERYVILLE, Calif., Feb. 19, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced today that it has learned that Osmotica Pharmaceuticals LLC and Vertical Pharmaceuticals...
February 13, 2018 16:01 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 22, 2018

EMERYVILLE, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report fourth quarter and full year 2017 financial results on...
February 09, 2018 17:26 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted five new...
February 08, 2018 09:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice

EMERYVILLE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that subgroup analyses of Parkinson’s disease patients taking amantadine immediate...
February 07, 2018 14:09 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Present at the LEERINK Partners 7th Annual Global Healthcare Conference

EMERYVILLE, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Founder, Chairman and Chief Executive Officer of Adamas,...
February 01, 2018 16:05 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal

EMERYVILLE, Calif., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that results of its Phase 2 proof-of-concept clinical trial of ADS-5102 (amantadine)...
January 29, 2018 08:30 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Closing of Its Public Offering of Common Stock, and Full Exercise of Underwriters’ Option to Purchase Additional Shares

EMERYVILLE, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the closing of its previously announced underwritten public offering of its common...
January 23, 2018 20:29 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Pricing of Public Offering of Common Stock

EMERYVILLE, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the pricing of its underwritten public offering of 3,000,000 shares of its common...
January 22, 2018 16:01 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Proposed Public Offering of Common Stock

EMERYVILLE, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it plans to offer $85 million of its common stock in an underwritten public...
January 08, 2018 16:41 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients

EMERYVILLE, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the full commercial launch of its flagship product, GOCOVRI™ (amantadine) extended...